...
首页> 外文期刊>Cancer Management and Research >Computed Tomography-Guided Percutaneous Cryoablation for ? Subcardiac Hepatocellular Carcinoma: Safety, Efficacy, Therapeutic Results and Risk Factors for Survival Outcomes
【24h】

Computed Tomography-Guided Percutaneous Cryoablation for ? Subcardiac Hepatocellular Carcinoma: Safety, Efficacy, Therapeutic Results and Risk Factors for Survival Outcomes

机译:计算断层扫描引导的经皮冷冻剂?瓣膜肝细胞癌:生存结果的安全性,疗效,治疗结果和危险因素

获取原文

摘要

Objective: To investigate the clinical safety, efficacy, therapeutic outcomes and risk factors of computed tomography-guided percutaneous cryoablation (CT-PCRA) for subcardiac hepatocellular carcinoma (HCC). Patients and Methods: In this study, patients with single HCC nodules located on the left lobe who subsequently underwent CT-PCRA were reviewed from July 2012 to August 2016. According to the definition of subcardiac HCC, the patients were grouped into the subcardiac HCC group (n=33) and the non-subcardiac HCC group (n=40). The technical success rates, tumour response rates, oncological outcomes including overall survival (OS) and recurrence-free survival (RFS) and complications were compared. Multivariate analysis was performed on clinicopathological variables to identify factors affecting long-term outcomes. Results: Seventy-three patients with subcardiac HCC were included in this study. After a median follow-up time of 37.8 months, 27.4% (20/73) of the patients died. The technical success and complete response rates were not significantly different between the two groups (p = 1.000; p = 0.590). The cumulative OS and RFS of the subcardiac HCC group were comparable to those of the non-subcardiac HCC group (p =0.820, p =0.922). Two major complications, intra-abdominal bleeding and right pleural effusion, were found at 2.2 and 3.1 months in the subcardiac HCC group, which were comparable with those in the non-subcardiac HCC group (p = 0.683). The multivariate analysis results showed that older age (hazard ratio [HR]: 2.382, 95% confidence interval [CI]: 1.884– 7.823; p = 0.038) and ALBI grade 2– 3 (HR: 3.398, 95% CI: 1.950– 6.058; p = 0.021) may be predictors of poor OS and that tumour size ≥ 3 cm in diameter (HR: 3.302, 95% CI: 2.232– 8.293; p = 0.012) may be a predictor of poor RFS. Conclusion: CT-PCRA for subcardiac HCC can be performed safely and efficiently and contribute to improving survival prognosis.
机译:目的:探讨临床安全,疗效,治疗结果和弓形虫癌癌(HCC)的经皮低温(CT-PCRA)的临床安全,疗效,治疗结果和危险因素。患者和方法:在本研究中,从2012年7月到2016年7月,审查了患者随后接受CT-PCRA的左侧叶的单一HCC结节的患者。根据蛛网膜病的定义,患者将患者分组到亚杆状病症中(n = 33)和非子心HCC组(n = 40)。比较了技术成功率,肿瘤反应率,肿瘤政治结果,包括总存活(OS)和无复发存活(RFS)和并发症。对临床病理变量进行多变量分析,以确定影响长期结果的因素。结果:本研究纳入七十三名患有副科技植入病症的患者。在37.8个月的中位随访时间后,27.4%(20/73)的患者死亡。两组之间的技术成功和完整的响应率没有显着差异(P = 1.000; p = 0.590)。累积OS和亚卡卡氏HCC组的RFS与非子心脏HCC组的累积OS(P = 0.820,P = 0.922)相当。在亚阶层HCC组的2.2和3.1个月内发现了两种主要并发症,腹部出血和右胸腔积液,其与非子心HCC组的那些相当(P = 0.683)。多变量分析结果表明,年龄较大(危险比[HR]:2.382,95%置信区间[CI]:1.884- 7.823; P = 0.038)和Albi级2-3(HR:3.398,95%CI:1.950- 6.058; p = 0.021)可以是差的缺陷的预测因子,肿瘤大小直径≥3cm(HR:3.302,95%CI:2.232-8.293; P = 0.012)可以是差的RFS的预测因子。结论:可安全有效地和有效地进行蛛网膜炎HCC的CT-PCRA,有助于提高存活预后。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号